期刊文献+

氯沙坦对原发性高血压患者左心室重塑的影响

Effect of losartan on left ventricular remodeing in essential hypertensive
暂未订购
导出
摘要 目的 :探讨氯沙坦在治疗原发性高血压中对左心室重塑的预防和逆转的作用。 方法 :12 0例原发性高血压患者随机分为氯沙坦组和对照组 (波依定组 ) ,入院时行超声心动图测定室间隔厚度 (IVSd)、左心室后壁厚度(LVPW ) ,并计算左心室重量指数 (LVMI)。治疗 6个月后复查上述指标。 结果 :(1)对照组治疗后LVPW和IVSd有变薄的趋势 ,但差异无统计学意义 ,治疗 6个月后LVMI下降且具有统计学意义 (P <0 .0 5 ) ;(2 )氯沙坦组治疗 6个月后LVPW、IVSd、LVMI均有改善 ,且具有统计学意义 (P <0 .0 5 ) ;(3)两组间降压幅度差异无统计学意义。 结论 :降低血压可抑制和逆转左心室重塑 ,但血管紧张素Ⅱ受体拮抗剂还具有降压外的消退和预防左心室肥厚及改善左心室舒张功能的作用 ,其抑制和逆转左心室重塑 ,保护心脏功能作用优于钙离子拮抗剂。 Objective: This study was to investigate the effect of losartan on left ventricular remodeling in essential hypertensive. Methods: One handred and twenty patients with essential hypertensive (heart funtion typeⅠ Ⅱ, hypertensive type 2 3) were randomly divided into 2 groups: losartan group, poyidin group. The parameters of LVMI, IVSd, LVPW were examined by echocardiography, and LVMI was measured before, and after therapy. Results: (1) In poyidin group, left ventricular septum thickness and posterior wall thickness showed the trend of decreasing, but have no statistically significant (P>0.05), leftventricular mass index reduced significantly (P<0.05) before and after therapy. (2) In losartan group, leftventricular septum thickness? posterior wall thickness and left ventricular mass index decreased significantly comparing with those before treatment and the controls (P<0.05). (3) There was no significant difference on range of decompression between two groups. Conclusion: Treatment of hypertension can depress and reverse left ventricular remodeling in patients with essential hypertension. But angiotensin Ⅱ antagonist has more effective to delay and depress the development left ventricular remodeling besides treatment of hypertension. Its effects on depreing and reversing left ventricular remodeling are better than that in poyidin group.
出处 《新疆医科大学学报》 CAS 2003年第5期416-418,共3页 Journal of Xinjiang Medical University
关键词 氯沙坦 原发性高血压 左心室重塑 losartan essential hypertension left ventricular remodeling
  • 相关文献

参考文献7

  • 1Devereux RB, Alonso DR, Lutas EM, et al. Echocardilgraphic asaessment of left ventricular hypertrophyt comparison to necropsy findinge[J]. Am J Cardiol, 1986, 57: 450-458.
  • 2Clenachen JM, Hendesen EH, Morris KI,et al. A possible mechanism of sudden death in hypertensive left ventricular hypertrophy[J]. Hypertens, 1987, 5(suppl 5): 620-625.
  • 3Schmieder RE, Marfus P,Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension:A meta-analysis of randomized double blind studies[J]. JAMA, 1996, 275:1057-1513.
  • 4Diez J, Fortuno MA, Ravassa S. Apoptosis in hypertensive heart disease[J]. Curr Opin Cardiol , 1998, 13:317-325.
  • 5Bjion Dahlof. Left ventricular hypertrophy and afigiotensin Ⅱantagonist[J]. AJH, 2001, 14: 174-182.
  • 6Ling Q, Guo ZG, Su Z, et al. Regression of cardiac hypertrophy and myosin isoenzyme patterns by losartan and captopril in renovasculaar hypertensive rats[J]. Acta Pharmacol Sin,1994, 15:206-210.
  • 7Chung B. Increased left ventricular mass after losartan treatment. [J]. Lancet, 1997, 349: 1743-1744.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部